Biotech financing and M&A activity continued to accelerate through high-value deals and public-market bids aimed at extending clinical programs. Parabilis Medicines filed for an IPO while positioning for Phase 3 execution of its Wnt/beta-catenin pathway inhibitor zolucatetide in desmoid tumors. The company’s timeline includes planned Phase 3 funding and continued work across Phase 1 efforts in multiple indications, supported by earlier FDA fast-track and orphan designations. The IPO plans followed Parabilis’ partnership with Regeneron, a collaboration structured around Antibody-Helicon Conjugates and stand-alone Helicons, with potential payments that could reach about $2.3 billion plus milestone and royalty components. The deal structure underscores the strategy of using peptide-stabilized platforms to access flat intracellular targets where traditional small molecules have struggled. For investors and developers, the combination of large private funding, strategic partnerships, and an IPO push highlights a renewed appetite for mature startups with concrete clinical datasets and platform differentiation.